Physician

Syed Asghar Hassan Rizvi, MD

According to 2025 Medicare claims, Syed Rizvi, MD (NPI: 1770511446) practices psychiatry in the Providence-Warwick, RI-MA market, with the plurality of this provider's patient population coming from Providence, RI. This provider's primary affiliated billing organization is BROWN NEUROLOGY (NPI: 1366486102; TIN: 05-0448314) and primary practice location at 02903-4923. Rizvi is affiliated with the Lifespan Health Alliance, LLC (ACO ID: A3336), participating under the MSSP model.

Rizvi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 168 traditional Medicare patients, billed 145,725 HCPCS/CPT codes, and received $1,001,905 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 2,897 prescription claims across 299 beneficiaries totaling $1,832,935 in drug costs, led by Kesimpta Pen (Ofatumumab). 2023 DME data shows 36 claims. Open Payments data shows 7 records totaling $5,272. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $368,881 to $1,001,905. In contrast, Part D prescription costs have moved from a higher plateau to a lower plateau, from $3,776,678 to $1,832,935. For DME billing, this smaller-volume category fell sharply in recent years, from $17,992 to $2,865.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	300	29,441	$368,881
2016	301	43,601	$654,008
2017	260	44,278	$796,963
2018	292	39,247	$759,091
2019	281	34,463	$837,653
2020	221	36,832	$931,521
2021	198	36,528	$1,066,977
2022	185	31,297	$888,490
2023	147	23,932	$657,487
2024	168	145,725	$1,001,905

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	193	2,896	$3,776,678
2016	222	3,170	$3,916,093
2017	235	3,394	$3,760,029
2018	241	3,276	$3,395,379
2019	235	3,079	$2,610,058
2020	256	3,074	$2,587,233
2021	241	2,794	$2,138,107
2022	254	2,757	$2,008,408
2023	272	2,979	$1,953,622
2024	299	2,897	$1,832,935

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	42	$3,009
2016	N/R	13	$711
2017	N/R	44	$1,859
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	12	$1,438
2021	N/R	12	$281
2022	N/R	N/R	N/R
2023	N/R	36	$4,367
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	20	20	$164
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	41	55	$132
96413	Administration of chemotherapy into vein, 1 hour or less	20	34	$96
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	82	101	$81
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	29	248	$51

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Kesimpta Pen	Ofatumumab	26	756	$273,148
Aubagio	Teriflunomide	21	870	$246,528
Ampyra	Dalfampridine	43	1,350	$191,701
Fingolimod	Fingolimod Hcl	50	1,500	$100,250
Copaxone	Glatiramer Acetate	14	420	$97,998

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	7	$5,272	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Syed Asghar Hassan Rizvi, MD?

Tedicare shows public-source Medicare data for Syed Asghar Hassan Rizvi, MD (NPI 1770511446), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Syed Asghar Hassan Rizvi, MD have ACO affiliation data?

Syed Asghar Hassan Rizvi, MD is shown with ACO affiliation data for Lifespan Health Alliance, LLC (MSSP, ACO ID A3336).

What billing organization is linked to Syed Asghar Hassan Rizvi, MD?

Syed Asghar Hassan Rizvi, MD is linked to BROWN NEUROLOGY (billing NPI 1366486102) in the available physician profile data.

Does Syed Asghar Hassan Rizvi, MD have Open Payments data?

Syed Asghar Hassan Rizvi, MD has 7 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.